A flawed Covid study gets Trump's attention — and FDA may pay the price

A flawed Covid study gets Trump's attention — and FDA may pay the price

A flawed Covid-19 study gets the White House’s attention — and the FDA may pay the price

By MATTHEW HERPER

GEORGE FREY/AFP VIA GETTY IMAGES

The FDA risks being pulled into an ugly political fracas over whether to permit more patients to be treated with hydroxychloroquine.

READ MORE